Regen BioPharma (RGBP) Stock Price, News & Analysis

Company Overview

Regen BioPharma Inc is a clinical-stage biotechnology company focused on the development of regenerative medicine and immunotherapeutic products. The company’s core activities include the design, development and potential commercialization of stem cell–based therapies and DNA-based vaccines targeting oncology and infectious diseases. Regen BioPharma’s proprietary technology platforms include a stem cell immunotherapy platform, an extracellular vesicle (EV) delivery system and the REXgenero gene expression system, which supports modular vaccine and therapeutic design.

The company’s pipeline features DNA vaccine candidates for human papillomavirus (HPV) and additional oncology indications, alongside preclinical programs leveraging exosome-based delivery to enhance immunomodulatory and regenerative outcomes. Regen BioPharma is advancing its lead assets through initial proof-of-concept studies while optimizing manufacturing processes to support scalable clinical development.

Founded in the early 2000s and headquartered in Houston, Texas, Regen BioPharma has established strategic collaborations with academic research centers and contract research organizations to bolster its discovery and development efforts. The company operates primarily in North America and is evaluating licensing and co-development opportunities to extend its geographic reach into Europe and Asia.

Backed by an experienced management team and a scientific advisory board with expertise in cell therapy and vaccine development, Regen BioPharma continues to pursue regulatory clearances and strategic partnerships. Its integrated approach to stem cell biology and gene-based immunotherapy positions the company at the forefront of next-generation treatment modalities.

Key Stats

• Today's Range: $0.09 to $0.12
• 50-Day Range: $0.04 to $0.09
• 52-Week Range: $0.02 to $0.27
• Volume: 136,457 shs
• Average Volume: 22,646 shs
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

RGBP Stock Analysis - Frequently Asked Questions

How have RGBP shares performed this year?

Regen BioPharma's stock was trading at $0.0601 at the beginning of the year. Since then, RGBP stock has increased by 48.1% and is now trading at $0.0890.

When did Regen BioPharma's stock split?

Shares of Regen BioPharma split before market open on Thursday, June 20th 2024.The 3-1 split was announced on Thursday, June 20th 2024. The newly issued shares were payable to shareholders after the market closes on Thursday, June 20th 2024. An investor that had 100 shares of stock prior to the split would have 300 shares after the split.

How do I buy shares of Regen BioPharma?

Shares of RGBP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Regen BioPharma own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Regen BioPharma investors own include Meta Platforms (META), Trans Global Group (TGGI), Exxe Group (AXXA), DraftKings (DKNG), Enzolytics (ENZC), Alcoa (AA) and Airborne Wireless Network (ABWN).

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: Biotechnology
• Sub-Industry: Pharmaceutical Products
• Current Symbol: OTCMKTS:RGBP
• CIK: 1589150
• Web: www.regenbiopharmainc.com
• Phone: (619) 722-5505
• Fax: N/A
• Employees: 1
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A